If you've worked in CINV, none of this stuff on Sustol or the crappy company performance is unexpected. For you fools who drank the coolaid, stop whining and looking for someone to blame. It's a really satisfied market with great options. Deal with it and sell something. The bupivaciane based product actually addresses an unmet need. The 505b aprepitant should make some money, but only as a cheaper generic- because you'll never be able to promote lower risk of allergic reactions than Emend unless it is the primary endpoint in a Phase 3 trial and winds up in your label- and that's not going to happen. Happy to help- 'ya filthy animals!
No, I don't think so. The OP is right - Sustol blows chunks and Cinvanti is only going to sell if it's priced at the level of a generic or the contract on it is so amazing that practices jump for the profit. But considering that the IV market for NK-1s is so much bigger, payers will be paying attention and probably won't authorize Cinvanti unless there's a nice fat rebate in it for them. Which, of course, will take time for Heron to put in place and will erode margins. So what does this mean? It means the CINV franchise for Heron is crap on its own. It validates BioChronomer, and buys a bit of time for the pain product to get approved and launched. But Rob Rosen is smoking mushrooms if he thinks Sustol is going to have a hockey stick adoption curve after practices evaluate it. That was a pathetic attempt to buy time on Wednesday, Bobby.
Well, that certainly was a deadly slay. Like Trump, you simply label what you don't like as FAKE NEWS. Nice try, but it's not going to work. Everyone in this business knows that you're just trying to limp along with Sustol until 011 gets here. You're not liked in the offices, your contract blows, and the market research you're feeding to the market is skewed and misleading. You've got a rotten product and everyone knows it.
